News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Capital return
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent …
Sharemaestro market context Price below Trend Line 52 weeks -6.9% · Next-week setup negative 12.1%This article first appeared on GuruFocus. Core Operating Profit: Up 7% year-on-year, with 5% growth in institutional retirement, 10% in asset management, and 5% in retail. Core Operating EPS: Up 11% year-on-year, above the top end of the 6% to 9% guidance range. Operating …
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading …
Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. …
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and …
This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.
This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.
This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering …
Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.
Fulgent Genetics Inc (7F0) has released its Q1 2024 earnings report, showing an actual EPS of -€0.01, beating the consensus EPS of -€0.28. The company's revenue for the quarter was €55.93M, missing the expected €56.69M, and showing a YoY revenue growth decline of 2.54%. …
Analysts have issued a "Hold" consensus recommendation for Fulgent Genetics (NASDAQ:FLGT), with an average 12-month price target of $27.00. The company recently reported Q2 2026 revenue of $85.4 million, missing estimates, and a non-GAAP loss of $0.58 per share, which exceeded expectations. Management also …
Sharemaestro market context Price below Trend Line 52 weeks -6.9% · Next-week setup negative 12.1%Fulgent Genetics (NASDAQ:FLGT) reported disappointing quarterly earnings, missing analyst estimates for both EPS and revenue due to revenue-cycle issues, including delayed billing and lower collection rates. The company also reduced its full-year 2026 guidance, forecasting lower revenue and negative non-GAAP EPS. Despite these setbacks, …
Fulgent Genetics (FLGT) saw its stock price fall by approximately 18% after reporting a significant quarterly net loss of US$29.5 million and lowering its full-year guidance. The company's revenue increased slightly year-on-year, but profitability challenges persist, with widening losses and reduced non-GAAP gross margins. …
Fulgent Genetics Inc (FLGT) has released its earnings summary for the quarter ended June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance. Full access to the article is available through a TradingView subscription.
Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million, missing analyst estimates. The company lowered its full-year 2026 revenue guidance to $330-$340 million and non-GAAP loss to $63-$67 million, attributing the revisions to delays in its billing …
Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, a 20% sequential increase, but faced challenges from billing system transition issues that pressured collections and gross margins, leading to a $29.5 million GAAP net loss. The company lowered its 2026 revenue guidance to $330 …
Fulgent Genetics (NASDAQ:FLGT) has updated its FY 2026 earnings guidance, projecting an EPS of -$2.35 to -$2.22 and revenue of $330 million to $340 million, which falls below consensus estimates. The company also missed Q2 earnings expectations, reporting an adjusted EPS of -$0.58 and …
Search by ticker symbol or company name and select a result to open its chart.